ELEVATE, a Registry of Patients With Acute Hepatic Porphyria (AHP)

Condition(s) studied

Study summary

This global patient registry is being conducted to characterize the natural history and real-world clinical management of patients with AHP, and to further characterize the real-world safety and effectiveness of givosiran and other approved AHP therapies.

Eligibility

Primary outcome measure(s)

• Incidence of Selected Events of Interest in AHP Patients — Up to 6 years
  Selected events of interest are defined as hepatic events (including hepatic neoplasia), renal events, thromboembolic events, and pancreatitis.

Trial sites (30)

More Alnylam Pharmaceuticals trials in Italy